These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18154489)

  • 1. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Berenguer J; Bellón JM; Miralles P; Alvarez E; Castillo I; Cosín J; López JC; Sánchez Conde M; Padilla B; Resino S
    Clin Infect Dis; 2008 Jan; 46(1):137-43. PubMed ID: 18171229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
    Waters L; Stebbing J; Jones R; Michailidis C; Sawleshwarkar S; Mandalia S; Bower M; Nelson M; Gazzard B
    J Antimicrob Chemother; 2004 Aug; 54(2):503-7. PubMed ID: 15201230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
    HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.
    Jordan J; Cahn P; Goebel F; Matheron S; Bradley C; Woodcock A
    AIDS Patient Care STDS; 2005 Jan; 19(1):9-18. PubMed ID: 15665631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of HCV infection on glucose metabolism in pregnant women with HIV receiving HAART.
    Pinnetti C; Floridia M; Cingolani A; Visconti E; Cavaliere AF; Celentano And LP; Tamburrini E
    HIV Clin Trials; 2009; 10(6):403-12. PubMed ID: 20133271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.